NasdaqGM:CGEN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe.


Snowflake Analysis

Flawless balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Compugen's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CGEN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-0.3%

CGEN

-4.0%

US Life Sciences

-0.04%

US Market


1 Year Return

344.8%

CGEN

34.9%

US Life Sciences

17.1%

US Market

Return vs Industry: CGEN exceeded the US Life Sciences industry which returned 35.1% over the past year.

Return vs Market: CGEN exceeded the US Market which returned 16.8% over the past year.


Shareholder returns

CGENIndustryMarket
7 Day-0.3%-4.0%-0.04%
30 Day8.8%6.0%5.1%
90 Day40.7%18.5%19.5%
1 Year344.8%344.8%35.2%34.9%19.6%17.1%
3 Year408.8%408.8%98.4%97.1%42.5%33.3%
5 Year190.2%190.2%148.8%145.6%75.1%56.2%

Price Volatility Vs. Market

How volatile is Compugen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Compugen undervalued compared to its fair value and its price relative to the market?

10.4x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CGEN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CGEN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CGEN is unprofitable, so we can't compare its PE Ratio to the US Life Sciences industry average.

PE vs Market: CGEN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CGEN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CGEN is overvalued based on its PB Ratio (10.4x) compared to the US Life Sciences industry average (6.3x).


Next Steps

Future Growth

How is Compugen forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?

-17.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CGEN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CGEN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CGEN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CGEN is forecast to have no revenue next year.

High Growth Revenue: CGEN is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CGEN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Compugen performed over the past 5 years?

-3.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CGEN is currently unprofitable.

Growing Profit Margin: CGEN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CGEN is unprofitable, and losses have increased over the past 5 years at a rate of 3.9% per year.

Accelerating Growth: Unable to compare CGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CGEN is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (10.7%).


Return on Equity

High ROE: CGEN has a negative Return on Equity (-20.33%), as it is currently unprofitable.


Next Steps

Financial Health

How is Compugen's financial position?


Financial Position Analysis

Short Term Liabilities: CGEN's short term assets ($137.2M) exceed its short term liabilities ($8.1M).

Long Term Liabilities: CGEN's short term assets ($137.2M) exceed its long term liabilities ($8.4M).


Debt to Equity History and Analysis

Debt Level: CGEN is debt free.

Reducing Debt: CGEN has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CGEN has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: CGEN has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 7.1% each year


Next Steps

Dividend

What is Compugen current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CGEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CGEN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Anat Cohen-Dayag (53 yo)

10.42yrs

Tenure

US$940,723

Compensation

Dr. Anat Cohen-Dayag, Ph.D., has been the Chief Executive Officer at Compugen Ltd. since March 2010 and serves as its President since June 2009. Dr. Cohen-Dayag served as Vice President of Research & Devel ...


CEO Compensation Analysis

Compensation vs Market: Anat's total compensation ($USD940.72K) is below average for companies of similar size in the US market ($USD4.48M).

Compensation vs Earnings: Anat's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Anat Cohen-Dayag
CEO, President & Director10.42yrsUS$940.72k0.12%
$ 1.6m
Ari Krashin
Chief Financial & Operating Officer5.92yrsUS$594.13kno data
Elana Holzman
Director of Investor Relations & Corporate Communicationsno datano datano data
Donna Gershowitz
General Counselno datano datano data
Kirk Christoffersen
Senior Vice President of Corporate & Business Development3.67yrsUS$639.39kno data
Oliver Froescheis
Senior Vice President of Corporate & Business Development0.58yrno datano data
Dorit Amitay
Vice President of Human Resources13.58yrsno datano data
Zurit Levine
Senior Vice President of Technology Innovationno dataUS$382.05kno data
Henry Adewoye
Chief Medical Officer2.42yrsUS$635.58kno data
Yaron Turpaz
Senior VP & Senior Advisor of Computational Discovery0.75yrno datano data
Rivka Schwartz
Vice President Research and Discoveryno datano datano data
Martin Gerstel
Senior Advisor2.5yrsno datano data

3.1yrs

Average Tenure

53yo

Average Age

Experienced Management: CGEN's management team is considered experienced (3.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Anat Cohen-Dayag
CEO, President & Director10.42yrsUS$940.72k0.12%
$ 1.6m
Sanford Zweifach
Independent Director2.17yrsno datano data
Howard Soule
Member of Scientific Advisory Board7yrsno datano data
Gilead Halevy
Independent Director2.17yrsno datano data
Paul Sekhri
Independent Chairman of the Board2.83yrsno datano data
Kinneret Livnat-Savitzky
Independent Director2.17yrsno datano data
Drew Pardoll
Chairman of Scientific Advisory Boardno datano datano data
Antoni Ribas
Member of Scientific Advisory Board7yrsno datano data
Jean-Pierre Bizzari
Independent Director1.92yrsno datano data
Iain McInnes
Member of Scientific Advisory Board7yrsno datano data
Charles Drake
Member of Scientific Advisory Board7yrsno datano data
Miriam Merad
Member of Scientific Advisory Board3.42yrsno datano data

3.4yrs

Average Tenure

54yo

Average Age

Experienced Board: CGEN's board of directors are considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33.7%.


Top Shareholders

Company Information

Compugen Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Compugen Ltd.
  • Ticker: CGEN
  • Exchange: NasdaqGM
  • Founded: 1993
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.349b
  • Shares outstanding: 82.86m
  • Website: https://www.cgen.com

Number of Employees


Location

  • Compugen Ltd.
  • Building D
  • 26 Harokmim Street
  • Holon
  • 5885849
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CGENNasdaqGM (Nasdaq Global Market)YesOrdinary SharesUSUSDAug 2000
CGENTASE (The Tel-Aviv Stock Exchange)YesOrdinary SharesILILSAug 2000
CW9DB (Deutsche Boerse AG)YesOrdinary SharesDEEURAug 2000

Biography

Compugen Ltd., a clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/12 00:17
End of Day Share Price2020/08/11 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.